ARIAD (ARIA) Reports Statistically Significant Results From Phase 2 Trial of Oral Ridaforolimus
Tweet Send to a Friend
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced positive interim results from randomized phase 2 trial of oral ridaforolimus.
The study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
The study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
